# A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)

> **NCT00473382** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 382 (actual)

## Conditions studied

- Diabetes Mellitus
- Macular Edema

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** Sham injection

## Key facts

- **NCT ID:** NCT00473382
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2011-01
- **Final completion:** 2012-09
- **Target enrollment:** 382 (ACTUAL)
- **Last updated:** 2017-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00473382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00473382, "A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00473382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*